The prevailing paradigm in anti-aging research treats cellular senescence as a universal pathology to be cleared. However, when examining the Central Nervous System (CNS), this approach may be dangerously flawed. My hypothesis is that cellular senescence in the brain exhibits a context- and cell-type-specific duality, where senescent astrocytes and microglia play a critical protective role early in neurodegeneration (via transient SASP-mediated repair) but only become detrimental when they persist chronically.

Currently, the "pro-universal senolytics" camp advocates for blanket clearance (e.g., with dasatinib + quercetin) to rejuvenate brain function. Yet, recent studies show that senescent microglia transiently accumulate during demyelination to limit damage spread, and naturally decline during remyelination. If we indiscriminately clear these cells during the acute phase, we may disrupt the very repair mechanism that prevents runaway neuroinflammation.

I propose we must pivot from blanket "senolysis" to "senomorphics" or temporally-gated, cell-type-selective clearance. For instance, can we design interventions that exclusively target senescent Oligodendrocyte Progenitor Cells (OPCs) near Aβ plaques without disturbing the protective senescent microglia in the same region?

The true test lies in timing: applying targeted clearance during the precise transition window from acute repair to chronic pathology. Have any labs currently modeled this temporal gating in tauopathy mice?